Chronic phenytoin therapy causes resistance to some nondepolarising muscle relaxants. We have confirmed that this resistance is seen with vecuronium and suggest that at least a week of phenytoin therapy is required for a significant effect to develop. The mechanism of this resistance is not known. We have shown that an exaggerated rise in serum potassium after succinylcholine does not occur in patients with demonstrated resistance to vecuronium from chronic phenytoin therapy. This would suggest that significant extrajunctional acetylcholine receptor proliferation is an unlikely mechanism.
Vecuronium is the nondepolarising muscle relaxant (NDMR) of first choice for major neurosurgical procedures at our institution. It has often been apparent that the intermediate duration of action of this drug is dramatically shortened in some patients. In 1982 the first report of anticonvulsant-induced resistance to pancuronium appeared in the literature. 1 This resistance has subsequently been demonstrated to develop in association with both chronic phenytoin and carbamazepine therapy.2.3 Since 1982 other studies have confirmed that resistance, specifically in association with chronic phenytoin therapy, occurs to other muscle relaxants including metocurine, vecuronium, and possibly d-tubocurarine but not to atracurium. 4 -6 Neither the time course nor the mechanism of the development of this resistance has been fully elucidated. Several possible mechanisms have been proposed and include increased metabolism via enzyme induction, decreased sensitivity at the receptor sites, an increase in receptor numbers and increased end plate anticholinesterase activity.2.4. 6 Ornstein et al have demonstrated that for metocurine and vecuronium the mechanism is a pharmacodynamic interaction 4.6 and have suggested that chronic phenytoin use antagonises acetylcholine at the pre-junctional receptor resulting in either an increase in the sensitivity or an increase in the numbers of these receptors. 6 Resistance to NDMRs has been shown to occur in a large, diverse and apparently unrelated group of pathological states including burns,79 upper and lower motor neurone lesions, 1012 mUltiple sclerosis, 13 *F.A.N-Z.C.A., Consultant Anaesthetist. tF.A.N.Z.C.A., Senior Registrar. cerebral palsy, 14 disuse atrophy 15 immobilisation 16 and prolonged blockade with NDMRs themselves. 17.18 The resistance that has been described in patients treated with phenytoin,46 carbamazepine,2 steroids 19 and aminophylline 20 may therefore, in some cases, be attributable in part to the coexisting disease for which they have been prescribed.
There is increasing evidence to suggest that the common pathophysiological mechanism underlying the resistance in these conditions is the development of extrajunctional acetylcholine receptors (EACRs) as a result of partial or total deprivation of normal neuro-humoral stimulation at the neuromuscular junction. 13.21-2'
Phenytoin has several actions at the neuromuscular junction,26-28 principally an inhibitory effect on acetylcholine release at the prejunctional motor nerve terminal that, conceivably, over a period of time, could lead to a state of partial chronic chemical denervation and result in postjunctional receptor proliferation.
An exaggerated rise in serum potassium after the administration of succinylcholine occurs in many conditions 29 and is thought to be due to the efflux of intracellular potassium through ion channels associated with EACRs opened by the process of depolarisation. 30 We hypothesised that if EACR proliferation was responsible for the resistance to NDMRs seen in patients on chronic phenytoin therapy then we would expect there to be an increased rise in serum potassium after the administration of succinylcholine.
The aims of this study were, firstly, to investigate the time course of the development of the resistance to vecuronium in patients on phenytoin therapy and, secondly, to investigate the proposed mechanism for this resistance by using the rise in serum potassium as an indicator of the development of extrajunctional acetylcholine receptors.
PATIENTS AND METHODS
The study was approved by the Human Rights Committee of the University of Western Australia and written informed consent was given by all patients.
Patients undergoing elective neurosurgical procedures were eligible for entry into the study. Exclusion criteria included therapy with anticonvulsants other than phenytoin and conditions in which the administration of succinylcholine is known to cause an exaggerated hyperkalaemic response, such as significant upper or lower motor neurone lesions, disuse atrophy, immobilisation, myopathies and recent burns. Also excluded were patients with significantly raised intracranial pressure.
Fifty-six ASA 1-3 neurosurgical patents were studied and assigned to one of three groups. The Control group consisted of 22 patients who were not receiving any anticonvulsant medication. The Acute group consisted of 13 patients receiving phenytoin for less than seven days. The Chronic group consisted of 21 patients receiving phenytoin for seven days or more.
After a benzodiazepine premedication, peripheral venous, intra-arterial and central venous cannulae were inserted under local anaesthesia. The arm selected for neuromuscular monitoring was splinted with the wrist in slight extension and the fingers lightly taped so as to prevent excessive movement. After skin cleansing with an alcohol swab and mild dermabrasion, Datex disposable pregelled silver-silver chloride surface electrodes were positioned over the ulnar nerve at the wrist and over the hypothenar muscles for recording of the electromyographic (EMG) response using the Datex Relaxograph T\1. Blood was taken from the arterial line before the induction of anaesthesia for a baseline serum potassium and phenytoin level.
After pre-oxygenation, anaesthesia was induced with propofol 1.5 mg/kg and fentanyl 2 mcg/kg. Once the patient was asleep the Datex Relaxograph was calibrated and a reference response obtained. Thereafter a train-of-four (TOF) stimulus was applied every twenty seconds and the T1 (integrated EMG response to the first stimulus in the train-of-four expressed as a percentage of the control value determined prior to relaxant administration) and the T4:T1 ratio (ratio of the fourth to the first response in the TOF) were recorded. Anaesthesia was maintained with 60070 nitrous oxide in oxygen and propofol as a continuous infusion at an initial rate of 10 mg/kg/hr, then titrated to individual requirements. No volatile anaesthetic agents were used and the end-tidal partial pressure of carbon dioxide was maintained between 30 and 35 mmHg. Unlike the volatile anaesthetic agents, propofol, at the doses used in clinical practice, does not have any effect on the neuromuscular blocking action of vecuronium. 3 1.1' Succinylcholine 1.0 mg/kg was given intravenously to facilitate intubation and blood was drawn from the arterial cannula for serum potassium estimations at one, three and five minutes later. The maximum increase in serum potassium was recorded.
When T1 had returned to 25070 of the control value, a loading dose of vecuronium 0.08 mg/kg was given. The recovery time (RT) from this initial dose of vecuronium was recorded as the time then taken for spontaneous recovery of the TOF ratio to 25070. Subsequently, incremental doses of vecuronium 0.02 mg/kg were given whenever the T4:T1 ratio returned to 25070 and a maintenance dose rate (MDR) was calculated from the average duration of the first three incremental doses. The three groups were compared using the twotailed unpaired t-test. Since three comparisons were being made the Bonferroni correction was applied and P value of <0.0167 was considered significant.
Simple and multivariable linear regression analyses were used for investigation of the relationship between the duration of phenytoin therapy and phenytoin levels and the relationships between these variables, as main predictors, and the measured parameters RT, MDR and postassium increase. A value of P<0.05 was considered statistically significant.
RESULTS
A total of 56 neurosurgical patients were studied. Craniotomy was performed on 31 patients for intracerebral tumour, 10 patients for arteriovenous malformations or aneurysm and three patients for other intracerebral conditions. There were three cranioplasties, five ventricular drains or shunts performed for hydrocephalus and four miscellaneous procedures.
The demographic data for the three groups were similar. There were no significant differences between the groups in either age or weight (Table 1) . Serum phenytoin levels were obtained in all but five patients (two in the Acute group and three in the Chronic group) on phenytoin therapy. The average serum phenytoin level was 9.7 mg/I in the Acute group AnaeHhesla and IflIensive lare, Vol. 2 
(range 3.6-24.0 mg/l) and 12.0 mg/l in the Chronic group (range 5.1-29.9 mg/l). This difference was not statistically significant (P=0. 34) .
Within the Acute group there was no statistically significant correlation between the duration of phenytoin therapy and the phenytoin level (r=0.34, P=0.31). Neither was there any statistically significant correlation between these variables in the Chronic group (r=O.1l, P=0.66).
After the administration of the initial loading dose of vecuronium 0.08 mg/kg all patients developed a neuromuscular blockade such that the T4:T1 ratio was less than 25070, however there was a sixfold variation in the recovery time (RT) ranging from a minimum of 11 minutes to a maximum of 66 minutes. The mean RT for the whole study group was 34.4 (SO 13.5) minutes. The average RT from the initial 0.08 mg/kg dose of vecuronium in the Control group was 42.2 minutes compared with 37.7 minutes in the Acute group and 24.2 minutes in the Chronic group (Figure 1 ). The maintenance dose rate (MOR) for the study group as a whole showed a similar sixfold variation in range from a minimum of 0.46 mcg/kg/min to a maximum of 2.98 mcg/kg/min. The mean MOR for the whole study group was 1.11 (SO 0.55) mcg/kg/min. The average MOR in the Control group was 0.83 mcg/kg/min compared with 0.92 mcg/kg/min in the Acute group and 1.55 mcg/kg/min in the Chronic group (Figure 2 ).
Significant differences in both the recovery time and the maintenance dose rate were therefore demonstrated between the Control and Chronic groups and between the Acute and Chronic groups. There were no significant differences between the Control and Acute groups for either of these variables.
The maximum rise in serum potassium was 1.1 mmol/l and the mean for the whole study group was Multivariable regression analysis failed to demonstrate a statistically significant relationship between the recovery time, as the dependent variable, and duration of phenytoin therapy and phenytoin level as the main predictors for the regression model (r-squared = 0.17, P=0.08). However, analysis of the relationship between maintenance dose rate and duration of phenytoin therapy and phenytoin level revealed a highly statistically significant correlation (r-squared = 0.48, P=0.0003). The parameter estimates for the contribution of the individual predictors suggest that the dominant factor was the influence of the phenytoin level (duration of phenytoin therapy P=0.02, phenytoin level P=0.0002). Finally there was no statistically significant relationship between the potassium increase and the duration of phenytoin therapy and phenytoin level (r-squared=O.Ol, P=O.83).
DISCUSSION
The absence of significant cardiovascular sideeffects has made vecuronium a frequently used nondepolarising muscle relaxant for neurosurgery, both for the facilitation of intubation and for continued maintenance of paralysis. Vecuronium normally has an intermediate duration of action that makes it suitable for administration either by repeated bolus or infusion, however, like all NDMRs, there is a wide interpatient variability of response as a result of both pharmacokinetic and pharmacodynamic factors. )11< Drug interactions, by any mechanism, will only serve to increase this unpredictability. Resistance to muscle relaxants may be potentially hazardous to the neurosurgical patient if patient movement, coughing or straining occurs as a result of an unexpected rapid return towards normal neuromuscular function. We have observed a sixfold variation in both the recovery time from an initial loading dose of vecuronium and in maintenance requirements, demonstrating just how unpredictable the individual response can be.
Although the serum phenytoin level was slightly less in the Acute group than in the Chronic group this was not statistically significant. The mean phenytoin level in the Acute group was just below the accepted therapeutic range of 10-20 mg/1. It was not unexpected that the longer a patient had been on phenytoin therapy the more likely it would be that a therapeutic level would be achieved. The elimination half-life of phenytoin is about 15-20 hours so that in the absence of a loading dose steady state levels would not be expected to be achieved for four or five days. Within the Acute group there was considerable variation in the dose regimens employed and a loading dose was not always given. However, despite these variations, the phenytoin level within the groups did not correlate with the duration of phenytoin therapy. Duration of phenytoin therapy was therefore the only significant difference between the Acute and Chronic groups.
Our results confirm that neurosurgical patients on chronic phenytoin therapy develop a resistance to vecuronium: however they would suggest that at least seven days of therapy is required for a clinically significant effect to be seen. The acute administration of phenytoin has been shown to enhance tubocurarineinduced neuromuscular blockade both in vitro and in an intact animal model. 26 The acute administration of phenytoin has been shown to enhance pre-existing vecuronium-induced neuromuscular blockade in humans 36 although acute resistance developing to alcuronium has also been reported. 37 The effect of phenytoin on neuromuscular transmission is complex with reports of both pre-and postjunctional blockade as well as a reduction in the synthesis of acetylcholine. 26.2-Paradoxically the chronic administration of phenytoin has been shown to produce resistance to several NDMR drugs.
Most studies have defined chronic administration as being phenytoin therapy for more than one week's duration. 2 . H The suggestion that this resistance is due to the development of extrajunctional acetylcholine receptors as a result of prolonged antagonism of acetylcholine at the neuromuscular junction is therefore an attractive hypothesis since it explains this paradox in response. Defining the Chronic group as phenytoin therapy for one week or more we believe is therefore logical since both steady state blood levels should have been reached and sufficient time will have been allowed for receptor proliferation to have occurred.
The resistance seen in many neurosurgical patients is multifactorial as these patients may also have physical factors known to produce acetylcholine receptor proliferation. All patients in this study had at most minimal neurological deficits and were not otherwise considered to be at risk of hyperkalaemia in response to succinylcholine. An additional factor of possible significance in this study, however, is the effect of dexamethasone administered to some of the patients. Whilst the numbers of patients on dexamethasone were not significantly different between the three groups the duration and doses of steroid therapy were highly variable. It was therefore not possible to analyse the significance of dexamethasone therapy in this study. There are conflicting reports in the literature on the influence of steroids on neuromuscular transmission in humans. Resistance to vecuronium has been reported in a single patient on testosterone therapy. J8 Resistance to pancuronium has been reported in an asthmatic patient treated with aminophylline and steroids. 20 However, this patient was critically ill requiring prolonged paralysis and ventilation for a two-week period which may in itself result in the development of resistance to NDMRs. 1 -. IX There is also retrospective evidence in man that neurosurgical patients on betamethasone demonstrate resistance to vecuronium. 19 Conversely five patients on chronic prednisone treatment for inflammatory bowel disease had a normal response to vecuronium. 39 Experimental work in animals has produced similarly conflicting evidence. 40 In a rat model increases in acetylcholine receptor numbers have been demonstrated in animals treated with phenytoin for 14 days and demonstrating resistance to metocurine. 41 We cannot categorically state that resistance to vecuronium in patients on phenytoin therapy is not due to EACR proliferation: this would require the estimation of EACR numbers using sophisticated techniques not available in our insti-Anaesrilesia and Imensive Care, Vol. 21, No. 2, April, 1993 tution. We have shown that there is no increased rise in serum potassium after succinylcholine in patients who have marked resistance to vecuronium.
In view of the fact that in other pathological states in which EACR proliferation occurs hyperkalaemia is a common clinical problem, we believe that significant EACR proliferation is not the mechanism in this case. We are not aware of any study that has specifically compared acetylcholine receptor numbers with the magnitude of the rise in serum potassium after the administration of succinylcholine. Ali and Goudsouzian have previously used the rise in potassium as an indicator of acetylcholine receptor numbers. 42 However in a recent study of the development of resistance to NDMRs from disuse atrophy it has been suggested that resistance develops before disuse-related K + efflux becomes significant. 43 The greatest rise in potassium in our study was 1.1 mmolll and the average was 0.22 mmolll. These values are similar to those reported in most previous studies of normal patients. [44] [45] [46] Thiopentone and, more recently, propofol have been shown to modify the increase in serum potassium after succinylcholine. [47] [48] [49] Despite this, isolated cases of cardiac arrest and massive hyperkalaemia have been reported in patients with intracranial pathology but without the usual underlying neurological defects recognised as being associated with the development of such a response to succinylcholine. [50] [51] [52] We are, however, confident that there is no risk of a dangerous hyperkalaemic response after succinylcholine in patients on chronic phenytoin therapy despite the associated resistance to nondepolarising muscle relaxants.
The analysis of the relationships between the phenytoin level and duration of phenytoin therapy and the measured parameters RT, MDR and potassium increase suggests that only the MDR correlates with the phenytoin level. The recovery time from the initial bolus dose of vecuronium (0.08 mg/kg) is primarily determined by redistribution. 53.54 A reduction in RT is therefore due either to increased redistribution, an increase in the initial volume of distribution (hence a reduction in peak plasma level) or a pharmacodynamic increase in the plasma concentration required to produce a particular degree of neuromuscular block. With subsequent small maintenance doses the elimination phase of previous doses becomes significant. 54.55 An increase in the MDR is therefore either due to a similar pharmacodynamic increase in the plasma concentration required to produce a particular degree of neuromuscular block, a decrease in the volume of distribution at steady state or an increase in drug clearance. Since the phenytoin level only appears to affect the MDR, an increase in vecuronium clearance or decrease in the volume of distribution are the most likely causes of this particular aspect of the interaction. The basis for such a pharmacokinetic interaction does not seem clear. Phenytoin-induced enzyme induction seems an unlikely mechanism as the hepatic elimination of vecuronium is mainly by biliary excretion of unchanged drug, there is also a large hepatic uptake of the drug which is thought to be responsible for its short duration of action. 56 Furthermore an interaction from changes in protein binding is also unlikely to be a significant factor since vecuronium is only about 30070 bound. 57 Small changes in protein binding and the free faction of vecuronium will therefore have minimal impact on drug clearance or free drug levels associated with particular degrees of neuromuscular blockade. 53 Significant increases in alpha-l acid glycoprotein have been shown to occur in rats chronically treated with phenytoin, the increase correlating with the phenytoin level. 41 If this also occurs in humans it may possibly result in a decrease in the apparent volume of distribution at steady state and an increase in MDR.
In summary, continued administration of phenytoin to patients results in a resistance to vecuronium which is seen as both a reduction in the recovery time from an initial dose and an increase in the subsequent maintenance dose rate. A clinically significant effect is seen after a week of phenytoin therapy. This resistance may be marked, leading to rapid and unexpected recovery of neuromuscular function. Careful monitoring of neuromuscular blockade is therefore of critical importance in this group of patients. The mechanism of the resistance remains in doubt. The results from this study suggest that the phenytoin level itself is an important factor that has previously not been described. The phenytoin level has been demonstrated to correlate specifically with the increase seen in maintenance dose rate suggesting that both pharmacodynamic and pharmacokinetic interactions are likely to be involved. The failure to demonstrate any evidence of EACR proliferation by indirect means suggests that decreased sensitivity to NDMR at the neuromuscular junction or increased endplate anticholinesterase activity need to be considered to explain a pharmacodynamic effect. It may be, however, that EACR proliferation results in a graded response, with resistance to the NDMR occurring at receptor numbers less than might be required for the development of a significant hyperkalaemic response to succinylcholine. Chronic phenytoin therapy is not a contraindication to the use of succinylcholine and cannot be implicated as a factor in the case reports of dangerous hyperkalaemia in neurosurgical patients.
